Financial Performance - The company's operating revenue for 2022 was ¥274,754,114.70, a decrease of 14.22% compared to ¥320,293,514.52 in 2021[21] - The net profit attributable to shareholders in 2022 was ¥9,012,396.69, representing a significant increase of 144.34% from a loss of ¥20,325,073.94 in 2021[21] - The net cash flow from operating activities was ¥25,217,762.02, an increase of 7.07% compared to ¥23,553,573.54 in the previous year[21] - The total assets at the end of 2022 amounted to ¥911,018,789.08, reflecting a growth of 6.61% from ¥854,556,164.94 at the end of 2021[21] - The net assets attributable to shareholders increased by 6.58% to ¥513,547,960.18 at the end of 2022, up from ¥481,848,410.05 in 2021[21] - The basic earnings per share for 2022 was ¥0.02, a turnaround from a loss of ¥0.05 per share in 2021, marking a 140.00% improvement[21] - The weighted average return on net assets was 1.80% in 2022, an increase of 6.01 percentage points from -4.21% in 2021[21] - The company reported a net profit excluding non-recurring gains and losses of -¥36,881,064.99 in 2022, a slight improvement of 6.35% from -¥39,383,459.22 in 2021[21] Revenue and Profit Trends - The company's total revenue for Q1 2022 was ¥73,230,987.79, which decreased to ¥53,583,090.97 in Q2, then increased to ¥71,049,140.92 in Q3, and reached ¥76,890,895.02 in Q4[23] - The net profit attributable to shareholders was ¥730,119.24 in Q1, but turned negative in Q2 and Q3 with losses of ¥2,543,950.58 and ¥1,806,463.72 respectively, before recovering to ¥12,632,691.75 in Q4[23] - Non-operating income for 2022 totaled ¥45,893,461.68, significantly higher than ¥19,058,385.28 in 2021, driven by gains from asset disposals and government subsidies[23] Industry Context - The pharmaceutical industry in China saw a revenue decline of 1.6% in 2022, with total revenue of ¥2,911.14 billion and a profit drop of 31.8% to ¥428.87 billion[28] - The government health expenditure in 2021 was ¥2,075.18 billion, accounting for 27.4% of total health spending, indicating a strong reliance on public funding in the healthcare sector[28] R&D and Innovation - The company is focusing on innovation and collaboration with small and medium enterprises to enhance competitiveness and resilience in the supply chain[29] - The company has developed multiple peptide drugs and 20 other therapeutic drugs, with significant international approvals including from the FDA and EMA[39] - The company focuses on the research and development of peptide products, with nearly 10 new peptide products in various stages of approval and development[42] - The company received FDA approval for the injection of Eptifibatide (75mg/100mL) and registration for Acetate Triptorelin injection (1ml:0.1mg)[49] Market Strategy - The company plans to enhance its R&D capabilities, focusing on the development of peptide raw materials and formulations, while increasing R&D investment and stabilizing the R&D team[85] - The company aims to expand its market presence through international collaborations, including patent licensing and joint development, to introduce advanced drug technologies into the domestic market[85] - The company plans to accelerate the submission of DMF and ANDA applications in the US and EU to enhance internationalization[47] Financial Management - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company reported a significant decline in investment income, down 52.81% to ¥4,689,841.85, primarily due to reduced financial investment returns[69] - The total net increase in cash and cash equivalents was -¥14,820,845.53, a decline of 193.68% compared to the previous year[66] Risk Factors - The company faces various risks including industry policy changes, drug price reductions, and financial risks, which are detailed in the report[5] - The company is exposed to financial risks from foreign exchange fluctuations and increasing accounts receivable and inventory, which may pressure operational funds[95] - The company is addressing the risk of drug price declines due to national policies by enhancing product quality and seizing market opportunities[94] Corporate Governance - The company emphasized its commitment to improving corporate governance and compliance with regulatory requirements, having held 3 shareholder meetings during the reporting period[101] - The board of directors held 13 meetings, ensuring diligent oversight and independent opinions on significant matters[103] - The company has established a fair and transparent performance evaluation system for directors and senior management, enhancing team cohesion and operational efficiency[104] Environmental Responsibility - The company has established a comprehensive pollution management system to comply with environmental regulations and reduce environmental risks associated with production[93] - The company invested over 4.84 million RMB in environmental protection facilities and daily expenses, focusing on construction, operation, maintenance, and testing of environmental protection equipment[168] - The company has not faced any administrative penalties due to environmental issues during the reporting period[168] Shareholder Relations - The company confirmed that it operates independently from its controlling shareholder, maintaining autonomy in business operations and decision-making[102] - The company has a clear asset ownership structure, with complete control over its production and operational facilities, ensuring no asset misappropriation by controlling shareholders[109] - The company has committed to a cash dividend distribution policy, aiming for a cumulative cash distribution of at least 30% of the average distributable profit over the past three years from 2021 to 2023[178]

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司投资者关系活动记录表 编号：014-20150325 | --- | --- | --- | |----------------|-------------------------|----------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 兴业证券 孙晓东 | | | 人员姓名 | | | | 时间 | 2015 年 3 月 25 | 日（星期三）上午 10:00 | | 地点 | 公司 | | | 上市公司接待人 | 董事会秘书 于晓风 | | | 员姓名 | | | | 投资者关系活动 | 1 | 、请介绍公司国际化发展战略。 | | 主要内容介绍 | 公司自 2008 | 年起就开始推动国际化，一直致力于用国际 | | --- | - ...

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司投资者关系活动记录表 编号：013-20150305 | --- | --- | --- | |----------------|------------------------|-----------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 东方证券 田加强 | | | 人员姓名 | 国投瑞银 张佳荣 | | | 时间 | 2015 年 3 月 5 | 日（星期四）下午 13:30 | | 地点 | 公司 | | | 上市公司接待人 | 董事会秘书 于晓风 | | | 员姓名 | | | | 投资者关系活动 | 1 | 、请介绍非公开发行股票事项的进展情况。 | | 主要内容介绍 | 公司股东大会已于 | 3 月 3 日审议通过了非公开发行股 ...

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司投资者关系活动记录表 编号：015-20200611 | --- | --- | --- | |----------------|-------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 东方光石（北京）实业有限公司刘佳鹏、刘子瑜、姜晚晴 | | 人员姓名 | | | | 时间 | 2020 年 6 月 11 | 日（星期四）下午 15:00 | | 地点 | 公司 | | | 上市公司接待人 | 董事会秘书 于晓风 | | | 员姓名 | 证券事务代表 李芬 | | | 投资者关系活动 | | 1、多肽产品在疫情期间销量情况及公司销售情况。 | | 主要内容介 ...

证券代码：002693 证券简称：双成药业 编号：017-20210524 | --- | --- | --- | --- | |-------------------------|-------------------------------------------------|----------------------------|-------------------------------------------------------------| | | | | | | | □ 特定对象调研 | □ 分析师会议 | | | 投资者关系活动 | □ 媒体采访 √ | 业绩说明会 | | | 类别 | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 通过全景网"投资者关系互动平台"（ 南辖区上市公司 | | http://ir.p5w.net ）参与"海 年度业绩网上集体说明会"的投资者 | | | 2020 | | | | 时间 | 2021 年 5 月 24 日 | 15:30 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥126,814,078.76, a decrease of 26.98% compared to ¥173,664,006.05 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was -¥1,813,831.34, representing a decline of 130.25% from ¥5,996,826.11 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥20,024,074.14, a decrease of 93.96% compared to -¥10,323,986.04 in the same period last year[22]. - The basic and diluted earnings per share were both -¥0.0045, a decrease of 145.00% from ¥0.01 in the same period last year[22]. - The weighted average return on net assets was -0.38%, down from 1.21% in the previous year[22]. - The company reported a total profit of -¥6.24 million for the first half of 2022, worsening from -¥2.46 million in the same period of 2021[161]. - The total comprehensive income for the first half of 2022 was -¥8.33 million, compared to -¥2.46 million in the first half of 2021, reflecting a worsening financial position[161]. Cash Flow and Investments - The net cash flow from operating activities improved by 28.26%, amounting to -¥5,933,898.11 compared to -¥8,271,445.49 in the previous year[22]. - The company’s investment activities generated a net cash outflow of CNY 67.71 million, a decrease of 235.72% due to reduced financial recoveries[44]. - The company reported a net cash outflow from investment activities of -67,707,160.06 CNY, compared to a positive inflow of 49,885,946.87 CNY in the previous year[165]. - Cash inflow from financing activities increased significantly to 65,382,403.00 CNY, compared to 20,398,640.00 CNY in the first half of 2021[166]. - The net cash flow from financing activities was positive at 60,234,308.56 CNY, a turnaround from -35,725,810.40 CNY in the same period last year[166]. Assets and Liabilities - Total assets at the end of the reporting period were ¥893,176,808.10, an increase of 4.52% from ¥854,556,164.94 at the end of the previous year[22]. - The company's total liabilities increased to CNY 315,513,938.49 from CNY 287,804,887.63, marking an increase of about 9.6%[155]. - The company's cash and cash equivalents at the end of the reporting period were approximately 8.27 million, a decrease of 1.60% from the previous year[54]. - The company's fixed assets accounted for 54.30% of total assets, with a value of approximately 485 million, down 4.41% from the previous year[54]. - The total liabilities decreased from 153,863,968.94 CNY at the end of 2021 to 138,357,271.42 CNY at the end of the first half of 2022, indicating a reduction of approximately 10.1%[187]. Market and Product Development - The company is recognized as a national high-tech enterprise, focusing on the research, production, and sales of peptide drugs, with multiple products approved and sold in developed countries[32]. - The main product, Thymosin Alpha 1 injection (brand name "Jitai"), has been approved for marketing in Italy and is included in the fifth batch of national drug centralized procurement[32]. - The company has developed over 20 therapeutic drugs, including peptide drugs and has received FDA approval for its injectable drugs, including Bevacizumab and Eptifibatide[35]. - The company plans to continue expanding its international market presence and has a robust pipeline for new product registrations in the U.S. and EU[41]. - The company is focusing on research and development of new technologies to drive future growth and innovation[180]. Risks and Challenges - The company faces various risks including industry policy changes, drug price reductions, and financial risks, which are detailed in the report[4]. - The company faces risks from rising raw material prices, which have increased production costs[68]. - The company is addressing potential risks from drug price reductions due to national policy changes[70]. - The company is actively managing foreign exchange risks by enhancing product value and utilizing prepayment, forward foreign exchange contracts, and letters of credit[72]. - The company has experienced impacts from public health events, affecting macroeconomic conditions and industry supply chains, but has taken measures to maintain normal operations[73]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The total number of shares held by the top 10 unrestricted shareholders includes 139,516,546 shares held by Hainan Shuangcheng Investment Co., Ltd., which is 51.5% of the total[141]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 33.64% of the shares, totaling 139,516,546 shares[138]. - The total equity attributable to the parent company at the end of the current period is CNY 577,662,000, reflecting an increase from the previous period[174]. - The company has implemented a stock option and restricted stock incentive plan, granting 7 million restricted shares at a price of 1.91 CNY/share and 7 million stock options at a price of 3.82 CNY/option[80]. Environmental and Compliance Measures - The company has implemented various environmental protection measures, including the construction of a wastewater treatment station and upgrades to its facilities to reduce volatile organic compounds emissions[90]. - The company has completed environmental impact assessments for several projects, including solvent recovery and production line expansions[92]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[95]. - The company is implementing measures to manage environmental risks and ensure compliance with new environmental regulations[70]. Research and Development - Research and development expenses increased to ¥5.15 million in the first half of 2022, up from ¥3.55 million in the first half of 2021, representing a growth of 45%[160]. - The company has a robust R&D pipeline with over 10 peptide products in various stages of approval and development, focusing on high market potential and complex synthesis[38]. - The company emphasizes the importance of attracting and retaining high-level technical talent for new drug development[71].

Financial Performance - The company's revenue for Q1 2022 was ¥73,230,987.79, a decrease of 12.57% compared to ¥83,759,538.77 in the same period last year[3]. - Net profit attributable to shareholders was ¥730,119.24, representing a significant increase of 121.62% from a net loss of ¥3,377,608.14 in the previous year[3]. - Basic earnings per share improved to ¥0.0018, up 118.00% from a loss of ¥0.01 per share in the same period last year[3]. - The company's net loss for the first quarter of 2022 was RMB 2,489,615.08, an improvement from a loss of RMB 8,153,305.80 in the previous year[27]. - The total comprehensive income for the first quarter was -2,497,156.47 CNY, improved from -8,165,356.09 CNY year-over-year[28]. Assets and Liabilities - Total assets increased by 3.37% to ¥883,386,626.72 from ¥854,556,164.94 at the end of the previous year[3]. - The total liabilities rose to RMB 317,411,619.14, up from RMB 287,804,887.63, indicating an increase of 10.4%[26]. - The company's inventory increased to RMB 57,577,217.54 from RMB 55,241,621.73, showing a growth of 4.2%[25]. Cash Flow - The net cash flow from operating activities decreased by 283.07% to -¥15,284,942.57, primarily due to reduced sales returns from price drops under national procurement policies[3][10]. - Cash inflow from operating activities totaled 80,330,695.21 CNY, down from 88,072,723.46 CNY year-over-year, reflecting a decrease of approximately 8.5%[31]. - Cash outflow from operating activities was 95,615,637.78 CNY, compared to 92,062,840.28 CNY in the same period last year, indicating an increase of about 3.0%[31]. - Cash flow from investing activities resulted in a net outflow of -41,225,949.49 CNY, a decline from a net inflow of 61,817,927.71 CNY in the previous year[31]. - Cash flow from financing activities generated a net inflow of 49,291,851.39 CNY, compared to a net outflow of -49,847,933.61 CNY in the same period last year, showing a significant improvement[32]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 26,017[13]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 33.86% of shares, totaling 139,516,546 shares[13]. - HSP Investment Holdings Limited, the second-largest shareholder, holds 15.76% of shares, totaling 64,915,479 shares[13]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for over 50% of total shares[13]. Stock Options and Incentives - The company has implemented a stock option and restricted stock incentive plan, granting 7 million restricted shares at a price of 1.91 RMB per share[15]. - The stock option plan includes 700,000 options granted at a price of 3.82 RMB per option, with 81 participants[15]. - As of April 2022, the company adjusted the stock option plan, reducing the number of options from 692.20 million to 684.25 million due to the departure of three participants[19]. - The first exercise period for the stock options is set from May 6, 2022, to May 5, 2023[20]. - The company has completed the registration of stock options and restricted stock grants, with a total of 75 participants in the stock option plan[18]. Other Income and Expenses - Research and development expenses decreased by 42.33% compared to the previous year, as some projects reached capitalization conditions[8]. - Other income increased by 546.27% year-on-year, mainly due to rewards received for the consistency evaluation of generic drug quality and efficacy[8]. - The company reported a 95.39% decrease in investment income, attributed to reduced financial management returns during the reporting period[8]. - Cash and cash equivalents decreased by 190.72% year-on-year, influenced by reduced sales returns and decreased financial management cash flow[10].

Financial Performance - The company's operating revenue for 2021 was ¥320,293,514.52, representing an increase of 18.87% compared to ¥269,441,762.99 in 2020[22] - The net profit attributable to shareholders was a loss of ¥20,325,073.94, an improvement of 61.89% from a loss of ¥53,329,409.90 in the previous year[22] - The net cash flow from operating activities was ¥23,553,573.54, a significant increase of 324.28% compared to -¥10,501,850.45 in 2020[22] - The total assets at the end of 2021 were ¥854,556,164.94, a decrease of 5.85% from ¥907,677,495.31 at the end of 2020[22] - The net assets attributable to shareholders decreased by 2.25% to ¥481,848,410.05 from ¥492,925,341.02 in 2020[22] - The basic earnings per share improved to -¥0.05 from -¥0.13, reflecting a 61.54% increase[22] - The company reported a total of ¥19,058,385.28 in non-recurring gains and losses for 2021, significantly higher than the previous year's amount of ¥4,926,651.22[29] - The company achieved a total revenue of 320,293,514.52 CNY in 2021, representing a year-on-year growth of 18.87%[51] - The net profit attributable to shareholders was -2,032.51 CNY, with a year-on-year increase of 61.89%[51] Revenue Sources - The revenue from product sales, after deducting non-main business income, was ¥303,558,131.42 in 2021, compared to ¥251,479,209.06 in 2020[23] - The company's total revenue for 2021 reached ¥303,558,131.42, representing a year-on-year increase of 20.71%[60] - The company's peptide products generated revenue of 172,370,500.73 CNY, which accounted for 53.81% of total revenue, reflecting a growth of 39.24% year-on-year[57] - The overseas revenue surged by 81.02% to ¥27,913,796.48, driven by increased export activities[60] - The market share of the main product, Thymosin Injection, was approximately 13%, ranking among the top in its category[48] Research and Development - The company invested 3,549.38 CNY in R&D in 2021, accounting for 11.08% of total revenue, although this represented a decrease of 43.07% compared to the previous year[52] - The number of R&D personnel increased by 33.80% to 95 in 2021, representing 22.84% of the total workforce[71] - The company aims to enhance its R&D capabilities and increase investment in R&D, focusing on the development of peptide APIs and formulations[96] - The company has successfully developed multiple peptide drugs and 20 other therapeutic drugs, with its main product, Thymosin Alpha 1 (brand name "Jitai"), approved for use in chronic hepatitis and immune enhancement[43] - The company has advanced laboratory equipment and a strong talent pool for peptide drug research and development, with nearly 10 peptide products in various stages of approval and development[46] Market and Industry Trends - The pharmaceutical industry in China saw a revenue increase of 20.1% year-on-year, reaching ¥2,928.85 billion in 2021, with total profits growing by 77.9%[33] - The domestic peptide drug market is experiencing annual sales growth, with increasing market share for domestic companies due to improved product quality and cost control[93] - The domestic peptide drug market is primarily dominated by foreign brands, indicating significant growth potential for domestic products[94] - The company faces challenges from increased competition in the peptide drug sector, driven by rising investment interest and regulatory changes[94] Governance and Compliance - The company has established a transparent performance evaluation system for its directors and senior management, promoting accountability and clear reward mechanisms[112] - The governance practices of the company align with the regulations set forth by the China Securities Regulatory Commission, ensuring compliance and integrity[113] - The company maintains complete independence from its controlling shareholders in terms of business, personnel, assets, organization, and finance[115] - The company has established an independent financial accounting system and makes its own financial decisions, with no shared bank accounts with controlling shareholders[116] - The company has implemented an internal audit system with two auditors to oversee financial reporting and internal controls[113] Environmental and Social Responsibility - The company has implemented a comprehensive pollution management system to comply with environmental regulations and reduce risks associated with waste emissions during production[103] - The company has passed environmental impact assessments for multiple projects, including solvent recovery and production expansion projects[169] - There were no administrative penalties imposed on the company due to environmental issues during the reporting period[172] - The company publicly disclosed its pollutant discharge permit execution status and monitoring results on its official website[173] Future Outlook - The company expects to achieve a business revenue of CNY 298.41 million and a total comprehensive income of CNY 8.13 million attributable to shareholders in 2022[97] - The company plans to continue expanding its product pipeline and aims to submit more DMF and ANDA applications in the U.S. and EU markets[49] - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20%[126] - The company plans to enhance market share through marketing strategies and diversify its product line via R&D and acquisitions to mitigate risks associated with product concentration[102] Shareholder Relations - The company has a commitment to prioritize the acquisition of assets or equity from its subsidiaries in case of competitive business operations[180] - The company has established a three-year shareholder return plan for 2021-2023, focusing on cash dividends[182] - The company will conduct annual cash dividends, contingent on positive distributable profits and sufficient cash flow[182] - The company has a structured remuneration decision process based on company performance and individual assessments[131]

Financial Performance - The company's operating revenue for Q3 2021 was ¥77,156,090.24, an increase of 1.42% compared to the same period last year, and a total revenue of ¥250,820,096.29 for the year-to-date, representing a 32.06% increase year-on-year [4]. - The net profit attributable to shareholders for Q3 2021 was a loss of ¥10,030,477.37, a decrease of 16.35% year-on-year, with a year-to-date loss of ¥4,033,651.26, which is an improvement of 84.29% compared to the previous year [4]. - The basic earnings per share for Q3 2021 was -¥0.02, unchanged from the previous year, while the year-to-date basic earnings per share improved by 83.33% to -¥0.01 [4]. - Total operating revenue for the third quarter of 2021 reached ¥250,820,096.29, an increase of 32% compared to ¥189,934,854.06 in the same period of 2020 [22]. - Net loss for the third quarter was ¥18,380,105.56, an improvement from a net loss of ¥40,206,899.50 in the previous year [23]. - The company reported a gross profit margin of approximately -14.4% for the third quarter, compared to -21.2% in the same quarter of the previous year [22]. - The company’s basic earnings per share improved to -0.01 from -0.06 year-on-year [24]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥6,694,673.44, reflecting a significant increase of 125.22% compared to the same period last year [4]. - The net cash flow from operating activities for Q3 2021 was ¥6,694,673.44, a significant improvement compared to the negative cash flow of ¥26,544,315.80 in the same period last year, indicating a turnaround in operational performance [26]. - Cash inflow from operating activities was ¥287,613,654.57, compared to ¥223,753,222.34 in the same period last year, marking a 29% increase [25]. - Total cash outflow from operating activities amounted to ¥280,918,981.13, up from ¥250,297,538.14 in Q3 2020, reflecting increased operational expenditures [26]. - The net cash flow from investing activities was ¥33,932,543.21, recovering from a negative cash flow of ¥54,071,973.46 in the previous year, suggesting improved investment management [26]. - Cash inflow from investment activities totaled ¥237,823,157.12, down from ¥508,841,081.23 in Q3 2020, indicating a decrease in cash recovery from investments [26]. - Cash outflow for capital expenditures was ¥203,890,613.91, significantly lower than ¥562,913,054.69 in the same quarter last year, showing reduced investment in fixed assets [26]. - The net cash flow from financing activities was negative at -¥35,904,922.61, compared to a positive cash flow of ¥44,176,763.51 in Q3 2020, indicating challenges in financing [26]. - The total cash and cash equivalents at the end of the period increased to ¥10,474,398.10 from ¥6,222,465.34, reflecting a positive cash position [26]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥866,027,099.88, a decrease of 4.59% from the end of the previous year [4]. - The total liabilities decreased to ¥100,522,340.03 from ¥129,408,743.59 year-over-year [19]. - The total liabilities decreased to ¥279,765,207.40 from ¥309,365,841.74, a reduction of approximately 10% [20]. - The total equity attributable to shareholders of the parent company increased slightly to ¥495,145,029.64 from ¥492,925,341.02 [20]. - The company’s long-term borrowings remain stable at ¥167,000,000.00 [19]. - The company experienced a 93.13% decrease in short-term borrowings compared to the beginning of the year, due to repayment of bank loans [7]. Operational Highlights - The company reported a 32.06% increase in operating revenue year-on-year, driven by increased product sales and processing business volume [9]. - The company's operating costs increased by 48.36% year-on-year, primarily due to higher product sales volume [9]. - The company reported a 1,190.12% increase in asset disposal gains year-on-year, mainly from the completion of the rights transfer of a product [9]. - The company received FDA approval for its product, Exenatide Injection, for market entry in the U.S. [16]. - The company plans to increase its European subsidiary's registered capital by €50,000, raising it from €10,000 to €60,000 [15]. - The company’s development expenditure increased to ¥87,986,446.94 from ¥69,915,599.62 year-over-year [19]. - Research and development expenses decreased to ¥6,868,488.95 from ¥8,303,280.00, reflecting a reduction of 17% year-on-year [23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,919 [13]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 33.86% of shares, totaling 139,516,546 shares [13]. Tax and Employee Costs - The company reported a total payment to employees of ¥40,151,021.90, which is an increase from ¥31,438,133.77 in the previous year, indicating higher labor costs [26]. - Tax payments amounted to ¥25,457,777.14, slightly up from ¥24,093,613.41 in Q3 2020, reflecting stable tax obligations [26]. Compliance and Standards - The company did not require adjustments to the opening balance sheet for the new leasing standards implemented in 2021, indicating compliance with the updated accounting regulations [27].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥173,664,006.05, representing a 52.53% increase compared to ¥113,857,607.78 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥5,996,826.11, a significant turnaround from a loss of ¥17,054,245.87, marking a 135.16% improvement[21]. - The basic earnings per share increased to ¥0.01 from -¥0.04, reflecting a 125.00% improvement[21]. - The net profit attributable to shareholders was CNY 5,996,826.11[34]. - The company's net profit for the first half of 2021 was CNY 15,506,697.52, showing a recovery from the previous year's loss of CNY 4,090,956.91[169]. - The company reported a profit attributable to the parent company of ¥5,996,826.11, compared to a loss of ¥17,054,245.87 in the previous year[150]. - The company reported a total comprehensive income for the first half of 2021 of CNY 15,506,697.52, reflecting a significant increase compared to the previous period[168]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 80.00%, reaching -¥8,271,445.49 compared to -¥41,351,368.57 in the previous year[21]. - The cash flow from operating activities showed signs of recovery, contributing positively to the overall financial health of the company[149]. - The company achieved a net increase in cash and cash equivalents of ¥5,852,151.13, a 150.41% improvement from a decrease of ¥11,609,495.30 in the same period last year[42]. - Cash and cash equivalents increased to ¥11,648,808.34, representing 1.35% of total assets, up from 0.64% last year, primarily due to the recovery of product rights transfer payments[51]. - The cash flow from investment activities generated a net inflow of CNY 49,885,946.87 thousand in H1 2021, contrasting with a net outflow of CNY 15,518,270.77 thousand in H1 2020[155]. - The net cash flow from financing activities was negative at CNY -35,725,810.40 thousand in H1 2021, compared to a positive inflow of CNY 45,235,182.22 thousand in H1 2020[156]. Assets and Liabilities - Total assets at the end of the reporting period were ¥864,612,737.32, a decrease of 4.74% from ¥907,677,495.31 at the end of the previous year[21]. - The total liabilities decreased to CNY 265,603,625.84 from CNY 309,365,841.74, a decline of approximately 14.14%[146]. - Short-term borrowings decreased significantly to ¥3,804,191.50, down from ¥55,407,118.64, reflecting a repayment of bank loans, resulting in a reduction of 5.66% in total liabilities[51]. - The company's current assets decreased to CNY 163,519,931.46 from CNY 197,500,462.66, representing a reduction of about 17.19%[144]. - The total equity attributable to the parent company at the end of the first half of 2021 was ¥598,311,000, reflecting changes in capital and reserves[161]. Research and Development - The company has developed multiple peptide drugs and 20 other therapeutic drugs, with key products including Thymosin Alpha 1 and Octreotide Injection[29]. - Research and development investment decreased by 66.60% to ¥16,021,887.06 from ¥47,972,168.85, as there were no new purchases of proprietary technology in the current reporting period[41]. - The company has a solid foundation in peptide product research and development, with nearly 10 new peptide products in various stages of approval and development[31]. Market and Sales - The revenue from peptide products increased by 67.74% to ¥87,769,815.31, accounting for 50.54% of total operating revenue[44]. - The revenue from the service sector surged by 388.46% to ¥13,365,407.99, reflecting the company's active engagement in commissioned research and development[44]. - The company's international sales saw a remarkable growth of 194.61%, with revenue from overseas regions reaching ¥13,841,828.83[44]. Risk Management - The company faces various risks including industry policy changes, rising raw material prices, and public health events, which are detailed in the risk management section[4]. - The company is focusing on cost control and management capability enhancement in response to increased competition in the pharmaceutical industry[33]. - The company is addressing the risk of drug price reductions due to national policies by enhancing product quality and seizing market opportunities[67]. Environmental and Quality Management - The company has advanced its environmental protection efforts, optimizing wastewater treatment processes and ensuring compliance with environmental standards[35]. - The company maintains a strong focus on quality management, with no safety or production incidents reported during the reporting period[34]. - The company has established a comprehensive pollution management system to comply with environmental regulations and reduce environmental risks[66]. Corporate Governance and Shareholder Matters - The company implemented the 2021 stock option and restricted stock incentive plan, granting 7 million restricted shares at a price of 1.91 CNY per share to 8 recipients and 7 million stock options at a price of 3.82 CNY per option to 81 recipients[76]. - The company held a temporary shareholders' meeting on March 18, 2021, to approve the incentive plan and related matters, with independent directors providing opinions on the plan[78]. - The total number of ordinary shareholders at the end of the reporting period is 27,208[130]. Financial Management and Investments - The total amount of entrusted financial management reached 12,048 million CNY, with an outstanding balance of 5,314.5 million CNY[114]. - The company has a diversified investment strategy, focusing on cash, bonds, and non-standardized debt assets[117]. - The expected return rate for the bank financial products is 2.70%, while the trust financial products have a return rate of 7.00%[114].